What’s In A Name? Janssen’s Loss Of Sovriad Was Gilead’s Gain With Sovaldi
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA initially rejected both sponsors’ preferred proprietary names for their hepatitis C treatments due to the risk of confusion with each other. Janssen had to settle for Olysio, its backup name for simeprevir, leaving Gilead to claim title to its preferred name for sofosbuvir.
You may also be interested in...
Review Of Reviews: Drug Review Profiles 2014
Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2014.
Review Of Reviews: Drug Review Profiles 2014
Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2014.
Olysio Reviewers
FDA staff that participated in the review of Janssen’s simeprevir for chronic hepatitis C.